Additionally, HCC patients with EpCAM+AFP+ demonstrated higher survival and portal vein invasion rates compared to those with EpCAM−AFP− [127], implicating its potency as an early biomarker and therapeutic target for HCC. This evidence concerns the gene AFP and hepatocellular carcinoma.